February 1st 2023
Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.
January 21st 2023
Effect of dietary nitrate on AMD progression
January 7th 2023Investigators conducted a cohort study to determine if there is a correlation between intake of nitrate and AMD progression based on previous suggestions that low nitrate levels in the diet may put patients at risk of AMD progression.
Read More
Pixium Vision finishes implantations in its European PRIMAvera pivotal trial in atrophic dry AMD
December 20th 2022The company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.
Read More
New potential mechanism for vision loss discovered
December 6th 2022Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.
Read More
AI-empowered diagnostic retina scans can help prevent heart and kidney diseases
November 10th 2022Mediwhale, an AI diagnostics company, aims for FDA approvals to increase non-invasive, early detection to save lives. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment.
Read More
EP. 5: EyeCon 2022: Last chance to earn those end-of-year CME credits
November 10th 2022This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.
Read More
Apellis to submit 24-month phase 3 data to FDA for pegcetacoplan NDA for geographic atrophy
November 4th 2022According to Apellis Pharmaceuticals, the submission will be a Major Amendment to the NDA, extending the review period by three months with an expected PDUFA target action date in February.
Read More
EYP-1901: A look at DAVIO and PAVIA clinical trial updates
November 3rd 2022Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.
Read More
Private practice vs academics: What do young ophthalmologists need to know?
November 2nd 2022Nicole Bajic, MD, and Neel S. Vaidya, MD, MPH, share their insights from when they were at this crossroads. Learn more clinical pearls on topics like this and more at Real World Ophthalmology’s virtual conference, “Top 10 Things I Wish I Knew Sooner,” this Saturday, November 5.
Read More
KYS Vision: clinical outcomes of remote physiologic monitoring for chronic retinal conditions
November 1st 2022The study is one of the first clinical trials to validate the clinical utility of real-world remote physiologic monitoring using an on-demand vision-as-a-service extension to the specialty retina clinic to enable remote monitoring of patients with chronic diseases such as AMD, diabetic retinopathy, and other retinal conditions.
Read More